Acute kidney injury requiring renal replacement therapy in severe vasodilatory shock is associated with an unfavorable prognosis. Angiotensin II treatment may help these patients by potentially restoring renal function without decreasing intrarenal oxygenation. We analyzed the impact of angiotensin II on the outcomes of acute kidney injury requiring renal replacement therapy.
Post hoc analysis of the Angiotensin II for the Treatment of High-Output Shock 3 trial.
Patients with acute kidney injury treated with renal replacement therapy at initiation of angiotensin II or placebo (n = 45 and n = 60, respectively).
IV angiotensin II or placebo.
Primary end point: survival through day 28; secondary outcomes included renal recovery through day 7 and increase in mean arterial pressure from baseline of ≥ 10 mm Hg or increase to ≥ 75 mm Hg at hour 3. Survival rates through day 28 were 53% (95% CI, 38%–67%) and 30% (95% CI, 19%–41%) in patients treated with angiotensin II and placebo (p = 0.012), respectively. By day 7, 38% (95% CI, 25%–54%) of angiotensin II patients discontinued RRT versus 15% (95% CI, 8%–27%) placebo (p = 0.007). Mean arterial pressure response was achieved in 53% (95% CI, 38%–68%) and 22% (95% CI, 12%–34%) of patients treated with angiotensin II and placebo (p = 0.001), respectively.
In patients with acute kidney injury requiring renal replacement therapy at study drug initiation, 28-day survival and mean arterial pressure response were higher, and rate of renal replacement therapy liberation was greater in the angiotensin II group versus the placebo group. These findings suggest that patients with vasodilatory shock and acute kidney injury requiring renal replacement therapy may preferentially benefit from angiotensin II.
1University of Tennessee College of Medicine, Chattanooga TN.
2Department of Critical Care Medicine, and Clinical and Translational Science, Center for Critical Care Nephrology, CRISMA, University of Pittsburgh School of Medicine, Pittsburgh, PA.
3Intensive Care Unit, Royal Melbourne Hospital, University of Melbourne, Grattan St, Parkville, Victoria, VIC, Australia.
4King’s College London, Guy’s & St Thomas’ Hospital, London, UK.
5Emory University, Department of Medicine, Atlanta, GA.
6University of Minnesota Medical School; Department Chair of Critical Care Medicine, Regions Hospital, Saint Paul, MN.
7Division of Nephrology and Hypertension, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN.
8Baylor University Medical Center, Dallas, TX.
9Adult Critical Care Unit, Department of Renal and Transplant Medicine, The Royal London Hospital, London, UK; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, UK.
10Division of Nephrology, Hypertension, & Renal Transplantation, Department of Medicine, University of Florida, Gainesville, FL.
11University of Texas Health Science Center at Houston, Houston, TX.
12Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany.
13Department of Clinical & Experimental Medicine, Faculty of Health Sciences, University of Surrey & Critical Care Unit, Royal Surrey County Hospital, Guildford, UK.
14La Jolla Pharmaceutical Company.
15The University of Melbourne, Melbourne, VIC, Australia; Austin Hospital, Heidelberg, VIC, Australia; Department of Intensive Care, Royal Melbourne Hospital, Melbourne, VIC, Australia; Australian and New Zealand Intensive Care Research Centre, Melbourne, VIC, Australia.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/ccmjournal).
A full list of the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators and study sites are listed in Supplemental Digital Content 1 (http://links.lww.com/CCM/D422).
Shannan Lynch, Jeff Jensen, Stew Kroll, Lakhmir Chawla, and George Tidmarsh are employees of La Jolla Pharmaceutical Company. The Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) trial was funded and supported by La Jolla Pharmaceutical Company. All other authors participated in the ATHOS-3 trial as investigators and work(ed) at institutions that were funded by La Jolla Pharmaceutical Company in support of the ATHOS-3 trial. Additionally, John R. Prowle has received consultancy fees and speaker honoraria from Nikkiso Europe GmbH and speaker honoraria from Baxter, Inc. Raghavan Murugan was awarded a research grant from La Jolla Pharmaceutical Company, and has received consulting fees from Beckman and Coulter, Inc and Bioporto, Inc. Kianoush Kashani has received a travel grant from La Jolla Pharmaceutical Company for the ATHOS-3 investigator meeting. Marlies Ostermann has received research funding and speaker honoraria from Fresenius Medical Care. Alexander Zarbock has received consulting fees from Astellas and Quark Pharmaceutical; speaker honoraria from Astute Medical, Baxter, Frensenius, and Braun; and grant support from Astute Medical and Quark Pharmaceutical. James Tumlin has received research grant support from La Jolla Pharmaceutical Company. Kevin Finkel will be a member of the La Jolla Pharmaceutical Company Speakers Bureau in 2018. Lawrence Busse has received consulting fees from La Jolla Pharmaceutical Company. Lui Forni has received research funding and honoraria from Fresenius, Baxter Gambro Renal, OrthoClinical Diagnostics, and La Jolla Pharmaceutical Company. Drs. Tumlin, Murugan, Deane, Ham, Szerlip, Prowle, Bihorac, Zarbock, and Bellomo’s institutions received funding from La Jolla Pharmaceuticals. Drs. Tumlin and Kroll disclosed off-label product use of angiotensin II for circulatory shock. Drs. Busse, Forni, and Kroll received funding from La Jolla Pharmaceutical Company. Dr. Szerlip’s institution also received funding from Baylor Research Institute. Dr. Finkel received funding from Alexion Pharmaceuticals (speakers bureau). Dr. Zarbock received funding from Baxter, Astute Medical, Fresenius, Braun, Astellas, and DFG. Dr. Forni also received funding from Ortho Clinical Diagnostics (honoraria). Drs. Lynch, Jensen, Kroll, Chawla, and Tidmarsh disclosed that they are employees of the trial sponsor (La Jolla Pharmaceutical Company). Dr. Tidmarsh disclosed work for hire. The remaining authors have disclosed that they do not have any potential conflicts of interest.
For information regarding this article, Email email@example.com
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.